Zevra Therapeutics Cash from Financing (TTM) Analysis

Zevra Therapeutics Inc (ZVRA)

5.19 +0.03 (+0.58%) USD | NASDAQ | May 07, 14:35

Cash from Financing (TTM) Chart

Historical Cash from Financing (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	28.46M
September 30, 2023	23.20M
June 30, 2023	-3.465M
March 31, 2023	9.335M
December 31, 2022	8.352M
September 30, 2022	5.739M
June 30, 2022	8.09M
March 31, 2022	34.09M
December 31, 2021	113.11M
September 30, 2021	115.93M
June 30, 2021	113.94M
March 31, 2021	76.01M
December 31, 2020	2.739M
September 30, 2020	2.435M
June 30, 2020	3.929M
March 31, 2020	3.289M
December 31, 2019	4.939M
September 30, 2019	28.55M
June 30, 2019	27.90M

Date	Value
March 31, 2019	27.94M
December 31, 2018	28.02M
September 30, 2018	4.716M
June 30, 2018	3.886M
March 31, 2018	2.609M
December 31, 2017	-0.203M
September 30, 2017	-0.628M
June 30, 2017	-2.592M
March 31, 2017	-2.512M
December 31, 2016	61.16M
September 30, 2016	60.38M
June 30, 2016	61.84M
March 31, 2016	121.05M
December 31, 2015	61.47M
September 30, 2015	60.94M
June 30, 2015	61.45M
March 31, 2015	27.06M
December 31, 2014	23.00M

Cash From Financing Definition

Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.

Read full definition.

Cash from Financing (TTM) Range, Past 5 Years

-3.465M

Minimum

Jun 2023

115.93M

Maximum

Sep 2021

31.93M

Average

9.335M

Median

Mar 2023

Cash from Financing (TTM) Benchmarks